Ocugen Inc. (OCGN)
OCGN trades on Nasdaq in Health Care, Biotechnology: Biological Products (No Diagnostic Substances). Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1372299/000162828026014435/0001628280-26-014435-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | OCGN on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) |
| Country | United States |
| IPO year | 2014 |
| SEC CIK | 0001372299 |
| SEC industry code | Biological Products, (No Diagnostic Substances) |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.4M |
| Net income | -$67.8M |
| Operating income | -$62.9M |
| Net margin | -1537.4% |
| Operating margin | -1425.7% |
| Revenue growth | +8.8% |
| Cash | $18.6M |
| Total assets | $43.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 59.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "After evaluating these conditions and management's plans, the Company has concluded that there is substantial doubt about the Company's ability to continue as a going concern within one year after the date these unaudited condensed consolidated financial statements are issued." | 10-Q 2026-11-04 |
| Cash and burn | $24.6M cash; operating cash flow -$15.9M a quarter. | Report 2026-09-30 |
| Shares outstanding | 339,306,603 (2026-10-30); 312,320,112 a year earlier; 256,502,434 three years earlier. | Cover page 2026-10-30 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-01-21 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers LLP, Philadelphia, Pennsylvania, United States | PCAOB Form AP 2026-03-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $26K, sold $589K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $2.0M | -$3.6M | -$15.7M | $24.6M | $1.8M | $4.8M | 10-Q 2026-11-04 |
| Q2 2026 2026-06-30 | $1.5M | -$24.9M | -$12.2M | $100.1M | $1.7M | $4.6M | 10-Q 2026-08-06 |
| Q1 2026 2026-03-31 | $1.5M | -$19.2M | -$21.8M | $31.9M | $29.2M | $4.5M | 10-Q 2026-05-08 |
| Q4 2025 2025-12-31 | -$193K | -$17.7M | -$14.0M | $18.6M | $28.8M | $4.4M | 10-K 2026-03-04 |
| Q3 2025 2025-09-30 | $1.8M | -$20.1M | -$12.9M | $32.9M | $28.4M | $5.4M | 10-Q 2026-11-04 |
| Q2 2025 2025-06-30 | $1.4M | -$14.7M | -$10.7M | $27.0M | $28.0M | $4.8M | 10-Q 2026-08-06 |
| Q1 2025 2025-03-31 | $1.5M | -$15.3M | -$19.4M | $37.8M | $27.7M | $4.5M | 10-Q 2026-05-08 |
| Q4 2024 2024-12-31 | $764K | -$13.9M | -$10.4M | $58.8M | $28.7M | $4.1M | 10-K 2026-03-04 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-01-21 |
| Latest annual report | 10-K | 2026-03-04 |
| Latest quarterly / interim | 10-Q | 2026-11-04 |
| Latest current report FORM 8-K | 8-K | 2026-11-10 |
| Latest proxy | DEFA14A | 2026-11-06 |
Source: SEC EDGAR submissions feed, 895 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -10.5% |
| 1 month | -6.4% |
| 3 months | -38.7% |
| Year to date | -38.7% |
| 1 year | -33.2% |
| From 52-week high | -66.6% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Biological Products (No Diagnostic Substances)
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| LXEO | Lexeo Therapeutics Inc. | $3.23 | +12.54% | $265.0M |
| PLX | Protalix BioTherapeutics Inc. (DE) | $3.03 | -0.66% | $255.5M |
| SABS | SAB Biotherapeutics Inc. | $3.00 | +1.35% | $270.3M |
| DTIL | Precision BioSciences Inc. | $7.28 | -3.77% | $277.6M |
| ALLO | Allogene Therapeutics Inc. | $0.8070 | -3.78% | $279.6M |
| AGEN | Agenus Inc. | $6.29 | -6.54% | $284.6M |
| CABA | Cabaletta Bio Inc. | $1.11 | -13.28% | $239.4M |
| EDIT | Editas Medicine Inc. | $1.87 | -13.82% | $288.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier